Company intelligence / Profile preview

Cytospire Therapeutics

Altrincham, Cheshire*, United Kingdomcytospire.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Cytospire Therapeutics has developed a differentiated portfolio of multispecific antibodies designed to engage all gamma delta T cell subtypes for cancer immunotherapy. Their approach aims to provide potent anti-tumor activity with improved safety over CD3-based engagers. The company’s technology remains preclinical, with no published human data or ongoing clinical trials as of mid–2025.

Therapeutic areas: ImmunologyOncology
Modalities: Monoclonal antibodyMultispecific antibody
Industry: Biotech

Drug pipeline

4 assets

CYT X300

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Cytospire Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytospire Therapeutics.

Explore the full profile